Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
-
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
-
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has...
-
CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will...
-
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore,...
-
FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort ...
-
CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
-
Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m....
-
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered...
-
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management...